Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma
SHANGHAI, China, Jan.
FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis
VICTORIA, British Columbia & ROCKVILLE, Md.
CDC study says Abbott's rapid COVID-19 antigen test may miss two-thirds of asymptomatic cases
Shortly after Abbott completed its delivery of 150 million rapid antigen tests to the federal government for widespread distribution against the COVID-19 pandemic, researchers at the Centers for Disea...
Eli Lilly’s Loxo Oncology Enters into $1.6 Billion Research and Collaboration Agreement with Merus N.V.
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company and Merus N.
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
TITUSVILLE, N.
Servier and MiNA Partner to Create Entirely New Class of Drugs
France-based Servier and U.
Boston Scientific Announces Agreement To Acquire Preventice Solutions, Inc.
MARLBOROUGH, Mass.
Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat)
KENILWORTH, NJ, USA I January 20, 2021 I Merck (NYSE.
FDA Grants Priority Review to Genentech’s Esbriet (pirfenidone) for Unclassifiable Interstitial Lung Disease
SOUTH SAN FRANCISCO, CA, USA, January 21, 2021.
Monoclonal antibody treatment by Eli Lilly found to cut risk of serious COVID-19, drugmaker reports
A drug developed by Eli Lilly and Company dramatically reduced the risk of developing symptomatic COVID-19 among nursing home residents, the company found.
Mark Cuban launches low-cost generic drug company
Billionaire Mark Cuban launched a drug company this week that is “dedicated to producing low-cost versions of high-cost generic drugs” and pledges “radical transparency” in pricing.
Doptelet® (avatrombopag) approved in the EU for treatment of ITP
STOCKHOLM, Sweden I January 20, 2021 ISwedish Orphan Biovitrum AB (publ) (Sobi™) (STO.
301
302
303
304
305
306
307
308
309